Gap in research means millions living with long-term consequences of cancer

Millions of people are living with the long-term consequences of cancer and its treatment, but currently there is very little research on the problems they face and how these can be tackled, according to the UK's National Cancer Research Institute (NCRI). Thanks to successes in research on diagnosing and treating cancer, more people are living longer with cancer and with the lasting side-effects of treatments. In the UK alone there were 2.5 million people alive following a cancer diagnosis in 2015 and this is predicted to rise to four million by 2030.

This growing population report side-effects that seriously affect their quality of life, but a combination of a shortage of funding, a lack of clear direction and relatively few researchers with expertise in this area have left a gap in cancer research.

New research presented at the 2018 NCRI Cancer Conference suggests that the issues faced by millions of people living with and beyond cancer could be identified and addressed with a set of ten new research priorities.

The new priorities have been developed by cancer patients, carers, doctors and nurses. Key questions include: how can treatment side-effects, such as fatigue, be prevented or managed; what is the impact on mental health; can lifestyle changes restore patients' health; and can we predict who will experience side effects?

The work was presented by Dr Feng Li of the NCRI. She explained: "The fact that millions of people are living with and beyond cancer is testament to the success of research on treatment and diagnosis. However, many of these people are living with the side-effects of cancer and treatment, and suffering from poor quality of life.

"There are not enough researchers studying these issues and there's very little funding currently available for this work. This is an enormous gap in our knowledge and it's one that can only begin to be filled if we have a starting point.

"We've looked at cancer research in the UK but the situation is similar around the world."

In response to the NHS's Cancer Strategy to achieve the best cancer outcomes, NCRI carried out this two-year project to determine priorities for research that will help people to live better with and beyond cancer.

The work included UK-wide surveys which attracted more than 3,500 responses. The final ten priorities were chosen at a workshop involving patients, carers, and health and social care professionals. It is the first time that patients and carers have determined priorities in this area.

Ceinwen Giles was diagnosed with stage IV non-Hodgkin lymphoma six weeks after the birth of her daughter. She is now Director of Partnerships and Evaluation at Shine Cancer Support and took part in the research. She said: "It is vitally important to put money into researching these ten priorities because they reflect the reality of living 'with and beyond' cancer and they were developed by patients and their carers, alongside health and social care professionals.

"I hope this project will highlight this important gap in cancer research and influence funders to support more research in this area."

Dr Li added: "There is a small amount of research going on in this area, supported by NCRI Partners and others, but we need to drastically increase the amount of research in the next five years and accelerate the translation of research into clinical practice."

The NCRI is now working with its Partner organisations, other funders, researchers and the NHS to translate the priorities into research and patient benefit. As well as increasing support from funders they plan to engage with researchers working in other chronic diseases to develop large multi-disciplinary research projects. Macmillan Cancer Support and Tenovus Cancer Care say they are already considering the priorities for their future research funding. NCRI is working with a number of funders and expects they will be able to support this initiative in the near future.

Sam Ahmedzai is Emeritus Professor of Supportive Care at the University of Sheffield, UK, Chair of the NCRI Supportive and Palliative Care Clinical Studies Group, and contributed to the research. He said: "Funders should pay attention and respond to the priorities. We need to make sure they are translated into funded research programmes, so that we can make much-needed progress in improving health and quality of life for those people living with the consequences of cancer."

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...